Myasthenie.com

Muscle Nerve. 2022 Jan 17. doi: 10.1002/mus.27500. Online ahead of print.

ABSTRACT

INTRODUCTION/AIMS: This study aims to investigate the frequency of acetylcholine receptor (AChR) binding antibody positivity via neuroautoimmunity panel testing, and describe its occurrence in a group of non-myasthenic disorders.

METHODS: This is a retrospective analysis of patients who underwent neuroautoimmunity antibody panel testing from 2010 to 2018 at Cleveland Clinic.

RESULTS: A total of 10,855 patients received neuroautoimmunity antibody panel testing, and 224 (2.1%) patients were positive for AChR binding antibody. Fifty-eight patients with known myasthenia gravis (MG) diagnosis and 11 patients with incomplete follow-up were excluded. Among the remaining 155 patients, 30 had newly diagnosed MG and 125 were non-myasthenic. In 35 patients, MG was within the initial differential diagnosis based on the clinical presentation. In contrast to non-myasthenic patients, myasthenic patients were more likely to have an initial clinical presentation raising suspicion for MG (73.3% versus 10.4%, p20% in patients with a clinical suspicion of MG is virtually diagnostic of MG. A total of 31 (24.8%) non-myasthenic patients carried coexisting autoimmune conditions.

DISCUSSION: Elevated titers of AChR binding antibody can be found frequently in non-myasthenic patients. Combined analysis of clinical presentation, AChR binding antibody titer and AChR modulating antibody results can be helpful in confirming an MG diagnosis. This article is protected by copyright. All rights reserved.

PMID:35037718 | DOI:10.1002/mus.27500


Source: https://pubmed.ncbi.nlm.nih.gov/3503771 ... 2&v=2.17.5